
Sign up to save your podcasts
Or


On this episode of Stock Movers:
- Apple (AAPL) shares jump on Monday after US President Donald Trump’s administration temporarily exempted phones, computers and chips from its so-called reciprocal tariffs. The exclusions, published late Friday by US Customs and Border Protection, narrow the scope of the levies by excluding the products from Trump’s 125% China tariff and his baseline 10% global tariff on nearly all other countries.
- Goldman Sachs (GS) shares rise after stock traders posted their highest quarterly revenue haul on record, riding a wave of volatility triggered by an emerging global trade war that’s roiled financial markets. Equity-trading revenue rose 27% from a year earlier to $4.19 billion for the first three months of the year, according to a statement Monday.
- Pfizer (PFE) shares edge lower after it halted development of its highest profile experimental drug, an obesity pill aimed at the blockbuster weight-loss market dominated by shots from Novo Nordisk A/S and Eli Lilly & Co., after it was linked to liver damage in a clinical trial.
See omnystudio.com/listener for privacy information.
By iHeartPodcasts4.6
1919 ratings
On this episode of Stock Movers:
- Apple (AAPL) shares jump on Monday after US President Donald Trump’s administration temporarily exempted phones, computers and chips from its so-called reciprocal tariffs. The exclusions, published late Friday by US Customs and Border Protection, narrow the scope of the levies by excluding the products from Trump’s 125% China tariff and his baseline 10% global tariff on nearly all other countries.
- Goldman Sachs (GS) shares rise after stock traders posted their highest quarterly revenue haul on record, riding a wave of volatility triggered by an emerging global trade war that’s roiled financial markets. Equity-trading revenue rose 27% from a year earlier to $4.19 billion for the first three months of the year, according to a statement Monday.
- Pfizer (PFE) shares edge lower after it halted development of its highest profile experimental drug, an obesity pill aimed at the blockbuster weight-loss market dominated by shots from Novo Nordisk A/S and Eli Lilly & Co., after it was linked to liver damage in a clinical trial.
See omnystudio.com/listener for privacy information.

406 Listeners

1,173 Listeners

2,175 Listeners

1,993 Listeners

427 Listeners

1,044 Listeners

1,320 Listeners

65 Listeners

64 Listeners

155 Listeners

87 Listeners

80 Listeners

81 Listeners

9 Listeners

11 Listeners